MAZE - רווח נקי למניה (EPS TTM) Maze Therapeutics, Inc.

Maze Therapeutics Inc (MAZE) is implementing Compass AI mapping to develop targeted drugs. Fundamental TTM earnings per share smooth out market shocks, and the indicator currently reaches -2.73. The company's growth is driven by liquidity and breakthroughs in Pompe disease therapy. Long-term financing is based on the patent protection of biologics and strategic partnerships with pharmaceutical behemoths.
פילוחי נתונים אנליטיים מרוכזים עבור Maze Therapeutics Corp (MAZE)

For Maze Therapeutics Inc (MAZE), whose operations focus on non-cyclical genetic drug development, net income per share over the last 12 months serves as a measure of capital allocation efficiency among shareholders. This indicator correlates bottom-line profit with the volume of issuance, allowing for an assessment of the biotech's financial resilience to market shocks through the lens of the real return on each share of ownership.